Stabilization without Rituximab after Disease Activation in an Alemtuzumab-Treated Patient with Multiple Sclerosis and a Literature Overview
To access the article please visit https://ijmsc.org/doi/10.7224/1537-2073.2018-030.
Release Date: November 30, 2019
Valid for Credit Through: November 30, 2020
Due to the complex challenges presented by multiple sclerosis, the ever-changing landscape of treatment options, and the evolving nature of care trends for patients, it is vitally important that clinicians treating MS patients have access to the latest information available regarding the disease. Journal articles are a perfect example of the timely education that is required to keep pace with the current clinical environment. These articles are normally fairly brief, which allows busy practitioners to fit education into their schedule in manageable blocks of time. Additionally, research which is newly published in journals, typically contains the most up-to-date information available, eliminating the need to check for accuracy.
These live and enduring webinars will offer continuing education credits for physicians, PAs, nursing professionals, and pharmacists (if applicable) and will occur every other month for five sessions. Following the live broadcast, the event will be archived for one year.
This activity has been designed to meet the educational needs of physicians, PAs, nursing professionals, pharmacists, and other members of the healthcare team involved in the management of patients with MS.
Upon completing this activity, participants should be better able to:
Identify the latest research and clinical information available in the literature with regard to MS diagnosis, treatment, and monitoring
Bryan D. Walker, MHS, PA-C, MSCS, Moderator
Duke University Medical Center
Chantal Kahovec, NP, Author
Saskatoon Multiple Sclerosis Clinic
Saskatoon, SK Canada
Michael C. Levin, MD, FRCPC, FAAN, FANA, Author
Saskatoon Multiple Sclerosis Clinic
Saskatoon, SK Canada
Commercial Support Acknowledgment
This activity is supported by educational grants from Celgene Corporation, EMD Serono, Genentech, and Mallinckrodt Pharmaceuticals.
Accreditation Statement and Credit Designation
In support of improving patient care, the Consortium of Multiple Sclerosis Centers (CMSC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The CMSC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.
The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Consortium of Multiple Sclerosis Centers designates this enduring material for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
The Consortium of Multiple Sclerosis Centers designates this enduring material for 1.0 contact hours of continuing education (1.0 in the area of pharmacology) for nurses.
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1 contact hours (.1 CEUs) to pharmacists who (1) complete the activity and (2) complete the evaluation form. The Universal Activity Number (UAN) for this activity is JA4008165-0000-19-008-H01-P. This is a knowledge-based activity.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
Certificate of Participation for Other Healthcare Professionals
A Certificate of Participation will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.
Disclosure of Financial Relationships
In accordance with the ACCME Standards for Commercial Support, CMSC requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC seeks to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
The program faculty reported the following relevant financial relationships that they have with commercial interests:
Chantal Kahovec, NP has disclosed no relevant financial relationships.
Michael C. Levin, MD, FRCPC, FAAN, FANA has disclosed no relevant financial relationships.
Bryan D. Walker, MHS, PA-C, MSCS (Planner) has disclosed the following relevant financial relationships: Consulting Fees: Biogen, EMD Serono, Novartis, and Sanofi-Genzyme; Speakers Bureau: Biogen.
John F. Kramer, PA-C (Planner) has disclosed the following relevant financial relationships: Consulting Fees: Biogen, EMD Serono, and Novartis Pharmaceuticals; Speakers Bureau: Alexion, Biogen, EMD Serono, and Genentech.
The planners, reviewers, editors, staff, or other members at CMSC who are in a position to control content have declared that they have no relevant financial relationships.
Disclosure of Unlabeled Use
CMSC requires faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
CMSC presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and the commercial supporters assume no liability for the information herein.
Method of Participation / How to Receive Credit
To successfully complete this activity, the participant must review the accreditation information, including learning objectives and faculty disclosures, view the webinar, complete the evaluation and claim credit.
- To complete the evaluation and claim credit, please click on the To Claim Credit button below or go to: highmarksce.com/mscare/.
- Log in with your user name and password*, or create a new account.
- Select the Enduring Materials tab, then select this activity from the listing and follow the instructions to complete the activity and receive your credit.
*If you do forgot your username or password, click on Forgot password. You will receive an email with a link to change your password.
This activity is best viewed using the most up to date version of Google Chrome, FireFox, or Microsoft Edge.
There is no fee to participate in this activity.
If you have any questions about this activity, please contact the CMSC at email@example.com or 201-487-1050, ext. 102.